V
Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
SIX:VIFN
Price:
166.15 CHF
0.48%
Market Closed
Updated:
May 17, 2024
Vifor Pharma AG
Interest Income Expense
|
Vifor Pharma AG
Interest Income Expense Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
V
|
Vifor Pharma AG
SIX:VIFN
|
Interest Income Expense
CHf30.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Interest Income Expense
-$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Interest Income Expense
-$90k
|
CAGR 3-Years
53%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Interest Income Expense
-CHf893m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
6%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Interest Income Expense
-$103m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Interest Income Expense?
Interest Income Expense
30.6m
CHF
30.6m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Interest Income Expense amounts to 30.6m CHF.
What is Vifor Pharma AG's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-14%
-14%
The average annual Interest Income Expense growth rates for Vifor Pharma AG have been -14% over the past three years .
You don't have any saved screeners yet
